Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $45.0K | — | — | — |
| Operating income | — | -$23.1M | -$29.0M | -$21.8M | -$20.2M |
| Operating margin | — | -51395.6% | — | — | — |
| Net income | — | -$25.4M | -$29.2M | -$22.1M | -$19.9M |
| Net margin | — | -56504.4% | — | — | — |
| EPS (diluted) | — | $2.99 | -$17.33 | -$35.70 | -$5.95 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | — | -$13.2M | -$27.0M | -$19.7M | -$21.3M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $2.24M | $590K | $2.17M | $9.81M | $5.82M |
| Total assets | $232M | $2.60M | $10.0M | $14.2M | $8.86M |
| Total liabilities | $16.5M | $43.4M | $18.3M | $12.2M | $5.10M |
| Long-term debt | — | — | $2.06M | $600K | $600K |
| Shareholders' equity | -$31.6M | -$50.4M | -$8.23M | $1.53M | $3.76M |
| Retained earnings | -$14.7M | -$70.4M | -$99.6M | -$122M | -$142M |
| Shares (wtd avg diluted) | 23.0M | 8.51M | 1.69M | 667M | 4.30B |
Every figure is extracted from Calidi Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.